The ALS Association this summer will host the second edition of its ALS Nexus, a conference bringing together researchers, healthcare professionals, advocates, patients, and caregivers in a quest to make amyotrophic lateral sclerosis (ALS) a more livable disease. The ALS Nexus 2025 event will take place Aug.
Qalsody (tofersen) halted disease progression and improved functional independence and mobility in people with amyotrophic lateral sclerosis (ALS) who received the treatment in a real-world setting, according to a study involving seven patients carrying mutations in the SOD1 gene. Data also showed robust and sustained declines in markers of…
A diet containing foods that quickly raise blood sugar is associated with slower amyotrophic lateral sclerosis (ALS) progression in people taking the standard treatment riluzole, according to data from a recent study. Scientists had previously found that a high glycemic index (GI) and glycemic load (GL) — two measures…
Constipation, a symptom experienced by about half of amyotrophic lateral sclerosis (ALS) patients, is associated with a significantly faster disease progression and poorer survival, according to a new study. Constipation was also linked to worse anxiety, depression, and sleep problems, data showed. “Objective assessment of these symptoms is critical…
Living next to arable cropland significantly raises the risk of developing amyotrophic lateral sclerosis (ALS), according to a new study in northwestern Italy. A significantly younger age at disease onset also was seen among those living near such farmland, which may include fields of cereals (wheat and barley), beans,…
A Chicago businessman and philanthropist — David Husman, founder and chairman of Heartland Real Estate Partners — has donated $20 million to advance research into amyotrophic lateral sclerosis (ALS) and patient care at Nova Southwestern University (NSU) in Florida. The gift, the largest given to research at the Fort…
Alchemab Therapeutics has partnered with Eli Lilly to develop new antibody treatments for amyotrophic lateral sclerosis (ALS) based on an approach that looks at the immune response of those with slower disease progression. Alchemab will identify, develop, and market up to five new antibody-based candidates. The company…
Team Gleason has expanded its collaboration with Synchron to raise awareness about the company’s BCI Community, an initiative that’s designed to help people with disabilities and their loved ones know more about brain-computer interface (BCI) solutions and gather insights to advance their development. BCIs can detect activity in…
The investigational oral therapies DNL343 and fosigotifator didn’t significantly slow disease progression in people with amyotrophic lateral sclerosis (ALS) compared with a placebo, and therefore failed to meet the main goal of their respective arms in the HEALEY platform trial. While they were found to be safe and well…
The number of people living with amyotrophic lateral sclerosis (ALS) in the U.S. is expected to steadily climb — by more than 10% — over this decade, increasing from an estimated 32,800 cases in 2022 to about 36,300 in 2030, according to a new study from researchers with the…
Get regular updates to your inbox.
